Positive News Coverage Somewhat Unlikely to Impact Aquinox Pharmaceuticals (NASDAQ:AQXP) Share Price

Media coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has been trending positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.1896484204777 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern’s analysis:

How to Become a New Pot Stock Millionaire

Shares of AQXP stock traded up $0.16 on Wednesday, hitting $14.44. The company’s stock had a trading volume of 39,313 shares, compared to its average volume of 117,140. The firm has a market capitalization of $338.74, a PE ratio of -6.75 and a beta of -14.95. Aquinox Pharmaceuticals has a 12 month low of $10.02 and a 12 month high of $17.42.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its earnings results on Monday, March 12th. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). equities research analysts expect that Aquinox Pharmaceuticals will post -2.27 EPS for the current fiscal year.

A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 16th. BidaskClub upgraded Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 11th. Guggenheim started coverage on Aquinox Pharmaceuticals in a research report on Thursday, February 8th. They set a “buy” rating and a $26.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a report on Sunday, February 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Aquinox Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $22.80.

TRADEMARK VIOLATION WARNING: “Positive News Coverage Somewhat Unlikely to Impact Aquinox Pharmaceuticals (NASDAQ:AQXP) Share Price” was posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/21/aquinox-pharmaceuticals-aqxp-earns-media-sentiment-score-of-0-31/1923552.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Insider Buying and Selling by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.